Rare Variant and Epigenomic Analysis in ME/CFS
Dauer: 36 Monate, Fördersumme: € 999.169
Predicting the evolution of relapse in Wilms tumour using drug sensitivity profiling and liquid biopsies
Fördersumme: € 999.538
Personalized risk assessment for embryonal tumor predisposition
Fördersumme: € 999.003
Functional Identification of Response Biomarkers to Advance Precision Oncology in Childhood Cancers
Fördersumme: € 999.357
Simultaneous assessment of muscle perfusion and mitochondrial function in ME/CFS
Fördersumme: € 40.000
Mechanism-based Reversibility Evaluation and Stratified Endophenotyping of Treatment-response in ME/CFS
Dauer: 36 Monate, Fördersumme: € 999.930